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Abstract 
Cervical cancer screening guidelines in the United States were revised in 2018 to include the 
option of primary human papillomavirus (HPV) testing. The transition to this screening method 
may face difficulties as Pap testing has been the primary screening modality in the United 
States. The objective of this study is to assess information, motivation, and behavioral skills 
associated with willingness to receive an HPV test instead of a Pap test among women. The 
sample included U.S. 812 women, ages 30 to 65 years. Participants completed an online survey 
in 2018. The Information, Motivation, and Behavioral Skills (IMB) model was used to measure 
predictors of willingness for HPV testing. The outcome variables were willingness to receive the 
HPV test instead of the Pap test, with and without time interval details. Logistic regression 
modeling was used with SAS 9.4. Over half of the sample (55%) were willing to receive the HPV 
test. For the information domain, HPV knowledge was significantly associated with willingness 
for HPV testing (OR=1.08, 95%CI 1.04-1.13). Significant motivating factors included: positive 
attitudes, social norms, perceived benefits, worry about cervical cancer, and worry about 
abnormal HPV tests. For behavioral skills, women were significantly more willing to get the HPV 
test if a provider recommended it (OR=2.43, 95%CI 1.53-3.87) and currently up-to-date on 
cervical cancer screening guidelines (OR=1.52, 95%CI 1.52-2.26). Addressing barriers and 
facilitators to willingness to transition to primary HPV testing over Pap testing is needed as the 
United States has updated guidelines for cervical cancer screening.  
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Introduction  
Human papillomavirus (HPV) is the most common sexually transmitted infection in the 
United States.1 Moreover, HPV causes >99% of cervical cancer cases.2 Cervical cancer rates 
among U.S. women have declined by over 50% since the implementation of routine 
Papanicolaou (i.e., Pap testing) cervical cancer screening in the 1950s.3 In 2006, a new tool for 
primary prevention became available with the introduction of HPV vaccination; presently, the 
Advisory Committee on Immunization Practices recommends the nonavalent HPV vaccine 
series for females and males ages 11-12 until age 26 .4-7 Following the sharp decrease in 
cervical cancer trends due to Pap testing screening advancements, cervical cancer incidence 
has remained largely unchanged due to screening, with approximately 13,170 new diagnoses of 
cervical cancer among U.S. women projected for 2019.8 The existence of primary HPV 
prevention does not eliminate the necessity of routine cervical cancer screening.6 
Most recently, cervical cancer prevention has shifted toward alternative secondary 
prevention approaches using primary HPV DNA testing (i.e., HPV test). Previous United States 
Preventive Services Task Force (USPSTF) guidelines from 2012 recommended routine cytology 
every 3 years to screen for cervical cancer among women ages 21 to 65 years and the option of 
co-testing with cytology and HPV testing every 5 years for women ages 30-65 years.9 In 2018, 
the USPSTF guidelines changed to include the option of primary HPV testing every 5 years for 
women ages 30-65 years, co-testing every 5 years, or Pap testing every 3 years.10  
When compared with Pap testing, primary HPV testing every 5 years was more 
efficacious at detecting cervical cancer for average risk women ages 30-65: Pap testing alone 
was less sensitive in detecting cervical intraepithelial neoplasias (CIN) 2 and 3.11-13 Because of 
improved screening sensitivity, primary HPV testing at 5-year intervals reduced cervical cancer 
deaths and reduced number of colposcopies per gained life-year when compared with Pap 
testing alone.11,12,14 Unlike Pap testing, samples for HPV testing can be collected by women and 
mailed for processing (i.e., self-sampling), serving as a potential strategy for increasing 
screening rates in under-screened populations.10 
 Other countries, such as Australia, have already transitioned to primary HPV testing for 
their national cervical cancer screening program.  However, Australia, a country that has led the 
way in cervical cancer prevention,15-17 faced difficulties in transitioning to HPV testing from Pap 
testing because of variations in HPV testing intentions, uptake, and willingness (i.e., 
acceptability18). Thus, there is a need to examine the acceptability of primary HPV testing in the 
U.S. with new guideline changes. Numerous studies have evaluated possible facilitators and 
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acceptability was a negative attitude toward the timing of screening intervals.19 A U.S. study 
revealed primary HPV testing every 3 years was the least acceptable, whereas annual Pap 
testing was most acceptable to women.20 Similarly, in a sample of Canadian women, willingness 
to attend primary HPV testing cervical cancer screening decreased from 84.2% to 54.2% when 
coupled with the extending of the screening interval to 4 years.21 In an Australian study, almost 
half of women aged 18-70 preferred having Pap tests annually, despite over 85% wanting 
concurrent HPV testing.22 Thus, the change in cervical cancer screening modality and interval in 
the United States must be further assessed with this changing USPSTF guidelines 
recommendation. 
In light of the newest guidelines, the aim of this study is to build on current primary HPV 
testing acceptability research by focusing on U.S. women aged 30-65 and their willingness to 
undergo primary HPV testing instead of Pap testing. Specifically, there is a need to explore how 
the change in type of test (i.e., Pap to HPV testing) and change in testing intervals (i.e., 3 to 5 
years) influences women’s willingness for HPV testing. This study aims to identify barriers and 
facilitators to 1) willingness to receive the HPV test instead of the Pap test and 2) willingness to 
receive the HPV test every 5 years instead of the Pap test every 3 years by assessing 
knowledge, motivation, and behavioral skills, the theoretical components of the Information-





 The target population for this study were women who would meet the guideline 
recommendation criteria for cervical cancer screening with HPV testing: inclusion criteria were 
women aged 30-65 years, and the exclusion criterion was having a hysterectomy. Women were 
sampled utilizing Qualtrics Online Panels, which recruits participants across the U.S. and 
provides respondents with small amounts of compensation (e.g., points, monetary). The 
sampling strategy oversampled for African American and Hispanic women due to the higher 
burden of cervical cancer among these populations.23 Participants were recruited in May-June 
of 2018 resulting in a total sample size of 812 participants. This study was exempt from the 
[BLIND] Institutional Review Board, and eligible women assented to participation after reading a 
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 The survey items were developed using the Information, Motivation, and Behavioral 
Skills (IMB) Model.24,25 The IMB Model identifies information, motivational issues, and 
behavioral skills to be implicated for a target population’s adoption of preventative behavior.24 
The IMB Model has been previously used to examined HPV vaccination among young adult 
women.26,27 The items on the survey were pilot tested with four women meeting the study 
inclusion/exclusion criteria.  
 During the survey, participants first responded to eligibility questions and knowledge 
questions about HPV. Once participants had completed the knowledge items, they were shown 
a diagram explaining the USPSTF recommendations for cervical cancer screening in 2012 and 
the draft recommendations for 2018. Additionally, participants were provided with a table 
comparing an HPV test and a Pap test based on a description from the draft 2018 
recommendations (see Supplementary Material).28 The purpose of providing women with this 
information was to ensure all participants were aware of the difference between the two tests. 
Similar methodology has been used in previous studies.29-31 This approach was especially 
needed for this topic as previous studies have reported many misconceptions regarding the 
purpose of the Pap test; many women incorrectly thought that Pap tests detected HPV and did 
not know that Pap tests screened for cervical cancer.32 
 Two outcomes were assessed. One outcome compared the two tests, regardless of 
testing intervals: willingness to receive the HPV test instead of the Pap test. The second 
outcome included testing intervals: willingness to receive the HPV test every 5 years instead of 
the Pap test every 3 years. Participants responded with a Likert scale of very willing, somewhat 
willing, neutral, somewhat unwilling, and not willing. Both variables were operationalized as 
willing (very willing and somewhat willing) and unwilling (neutral, somewhat unwilling, and not 
willing).  
 Predictor variables selected for the analysis were derived from the IMB Model and the 
current body of research regarding women’s HPV testing acceptability. Within the Information 
domain, HPV knowledge was assessed using a 16-item true, false, and don’t know scale,31 
which has been validated among a sample of Canadian parents.29 Response options were 
recoded as correct and incorrect (inclusive of don’t know). Correct responses were summed for 
the 16-items for a total HPV knowledge scale score (α=0.886).  
 Motivation variables included an HPV testing attitude scale, social norms, HPV testing 
benefit of less time at a doctor’s office, HPV testing benefit of less frequent discomfort, worry 
about cervical cancer, and what is most worrisome for testing outcomes. The 4-item HPV 
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years and after age 30 instead of a Pap smear every 3 years would be: accurate/safe/protect 
my health/acceptable.” There were 7-Likert response options of strongly agree to strongly 
disagree aggregated to produce a sum score (α=0.946). A subjective norms question was 
adapted33; “If national guidelines recommended having an HPV test to screen for cervical 
cancer instead of a Pap smear, most people who are important to me would think I 
should/expect me to have an HPV test instead of a Pap smear.” The 7-response Likert scale 
was operationalized as agree (strongly agree, agree, and somewhat agree), neither agree nor 
disagree, and disagree (strongly disagree, disagree, and somewhat disagree) due to the 
bimodal distribution of the variable. A question adapted from Gerend et al.34 asked “For you 
personally, what would be the main benefits (good things) of getting an HPV test every 5 years 
instead of a Pap test every 3 years?” Variables assessing two HPV testing benefits, less 
frequent discomfort and less time at the doctor’s office (response options yes, no), were 
included in a list of benefits.34 Worry about cervical cancer was adapted35 asking “How worried 
are you about developing cervical cancer?”. Five response options ranging from not worried at 
all to very worried were operationalized into three categories: not worried, slightly/somewhat 
worried, and quite/very worried. To assess which testing outcomes would be more worrisome,36 
participants were asked “What would worry you more?”: an abnormal Pap test, an abnormal 
HPV test, equally worrying, and neither. 
Behavioral skill variables included facilitators of the decision/skill, barriers to the 
decision/skill, and current adherence to cervical cancer screening guidelines. Variables to 
assess provider recommendation as a facilitator and stigma about having HPV as a barrier were 
adapted from a list of barriers and facilitators by Jayasinghe et al.19, asking “What would make 
deciding to have an HPV test instead of a Pap test easier for you?” and “What would make 
deciding to have an HPV test instead of a Pap test harder for you?”, respectively. The items for 
this analysis were selected based on the salience from previous literature on HPV testing.18 
Response options were yes and no. Adherence to cervical screening guidelines was assessed 
based on the 2012 USPSTF recommendations. Women who had Pap testing in the last 3 years 
(without co-testing) or women who had co-testing in the last 5 years were considered adherent 
to screening guidelines, otherwise they were considered non-adherent. 
For participant demographics, education attainment categories included less than high 
school, high school, some college or technical school, and college. Marital status categories 
included single, married, or other (e.g., widowed, divorced, etc.). Age was categorized by 
decade. Race was operationalized as Black, White or Caucasian, and Other categories, and 
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  Data Analysis 
 Aggregate data were received from Qualtrics Panels, and all analyses were conducted 
in SAS 9.4. Univariate and bivariate statistics analyses were performed for each binary outcome 
HPV testing willingness and HPV testing willingness with time component, respectively. Using 
predictor variables from the IMB model and demographic variables (see Measures), 
multivariable binary logistic regression models were estimated for both outcomes. No evidence 
of multicollinearity was observed (variance inflation factor<5). Adjusted odds ratios (aOR) and 




Of the 812 women in this sample, 55% of the respondents were willing to get the HPV 
test instead of the Pap test and 57% of the respondents were willing to get the HPV test every 5 
years instead of the Pap test every 3 years (Table 1). Overall, most respondents were White 
(68.1%), Non-Hispanic (81.4%), and married (49.8%). Most women fell between the ages of 30 
and 39 (39.8%) and had some college or technical school education (36.5%). Over half of 
women (54.3%) were slightly or somewhat worried about getting cervical cancer, and most 
women (71.4%) were adherent to the 2012 USPSTF cervical cancer screening guidelines. 
When asked what result would worry them more, most respondents reported that an abnormal 
HPV test and an abnormal Pap test were equally worrying (60.2%). Additionally, most women 
(63.6%) did not report HPV stigma as a barrier to HPV testing. Moreover, most participants 
identified less time in the doctor’s office (73.5%) and less frequent discomfort (70.3%) as a main 
benefit of HPV testing. In fact, most women (75.4%) reported that having a provider 
recommendation would facilitate selecting HPV testing over Pap testing.  
 
Willingness for HPV Test Compared to Pap Test 
 In multivariable analysis, a one-unit increase in knowledge score was associated with   
higher odds (aOR=1.08; 95%CI 1.04-1.13) of willingness to receive the HPV test instead of the 
Pap test. With regard to attitudes, women with more positive HPV testing attitudes (aOR=1.14, 
95%CI 1.10-1.19) and positive social norms for HPV testing (agree: aOR=2.01, 95%CI 1.37-
2.95) had higher odds of willingness for HPV testing. Additionally, women who perceived a 
benefit of less time in the doctor’s office and less frequent discomfort had higher odds to get the 
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had more than twice the odds (aOR=2.58; 95%CI 1.48-4.51) of being willing to receive the HPV 
test. Similarly, women who reported an abnormal HPV test worries them more, compared to the 
two tests being equally worrying, were more willing to receive the HPV test. 
 Regarding behavioral skills, we examined potential facilitators and barriers for deciding 
about an HPV test instead of a Pap test. Women reporting that a provider recommendation 
would make it easier to decide were more willing to receive the HPV test (aOR=2.43; 95%CI 
1.53-3.87). Women who were currently adherent to cervical cancer screening guidelines were 
more willing to receive an HPV test instead of a Pap test (aOR=1.52, 95%CI 1.02-2.26). For 
demographic characteristics, women with a college degree were less willing to receive an HPV 
test (aOR=0.58, 95%CI 0.35-0.94) compared to women with a high school degree. 
 
Willingness for HPV Test Every 5 Years Compared to Pap Test Every 3 Years 
  Similar results were observed in the multivariable model for the outcome of willingness 
for HPV testing every 5 years compared to Pap testing every 3 years. In this model, less time at 
a doctor’s office as a perceived benefit, worry about the type of abnormal test, and educational 
attainment were no longer statistically significant. The strongest effect observed was that, 
compared to those not worried about cervical cancer, women who were worried about cervical 
cancer had twice the odds of being willing to endorse HPV testing every 5 years compared to 
Pap testing every 3 years (aOR=2.01, 95%CI 1.17-3.43). 
 
Discussion 
Given the recent transition of U.S. cervical cancer screening guidelines to include 
primary HPV testing, there is a need to examine women’s willingness to engage in this 
prevention behavior. Australia has recently faced resistance from women when the cervical 
cancer screening program transitioned from Pap testing to primary HPV testing.17 In the present 
study we found that more than half of the sample was willing to have primary HPV testing 
instead of Pap testing as a mode for cervical cancer screening. 
 Using the IMB Model as a framework, knowledge of HPV was significantly associated 
with willingness to use HPV testing. Burger et al., (2014) also reported that increased HPV 
knowledge was associated with increased HPV test acceptability among Norwegian women.35  
In this study, motivating factors, i.e., positive attitudes and social norms about HPV testing, were 
significantly related to willingness for primary HPV testing. Similar findings were reported for 
positive attitudes and indirect subjective norms (e.g., physician, friends, partner, cancer agency) 
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4 years among Canadian women.21,33 In this study, women’s beliefs for perceived benefits for 
less time in a doctor’s office and less frequent discomfort were also found to be significant 
factors associated with HPV testing. These perceived benefits may be similar to beliefs 
regarding lengthened Pap testing intervals. Gerend et al. (2017) described the most commonly 
reported potential benefits of less frequent Pap testing to be reduced cost, dislike of annual Pap 
tests, and more convenience in a US sample of women ages 21-65 years.34 In contrast, less 
frequent visits were reported qualitatively as a past concern for implementing widened 
screening intervals, as women have often preferred annual cervical cancer screening.21  
Additionally, a concern regarding the transition to HPV testing has been women’s 
negative emotional reactions to a positive HPV test compared to an abnormal Pap test, as seen 
in a qualitative study with Hispanic women.37 Similar findings among young women of 
reproductive age were found in a mixed-methods study assessing psychosocial effects of HPV 
test results and abnormal Pap smears. Women reported a sense of stigma and shame related 
to the diagnosis of HPV that was compounded by the fear of cervical cancer stemming from 
abnormal Pap results.38,39 Women in this study were more willing to receive the HPV test if they 
reported that beliefs that they were worried about cervical cancer and more worried about an 
abnormal HPV test.  
Women who were adherent to 2012 cervical cancer screening guidelines were more 
willing to receive an HPV test compared to Pap test. The key facilitator to this decision may 
ultimately rely on a provider recommendation. Women in the sample had more than two times 
the odds of being willing to receive an HPV test compared to a Pap because a provider 
recommendation would make that decision easier. The importance of provider recommendation 
is noted in another study among US women, where over two-thirds were willing to undergo less 
frequent screening (screening every 3 to 5 years versus annually) if it was recommended by 
their provider.34 The US Community Preventive Services Task Force recommends one-on-one 
patient-provider education to increase cervical cancer screening,40 so this finding aligns with this 
evidence-based recommendation. However, previous research has found providers are more 
likely to recommend more frequent screening, some of which stems from patient requests.41,42 
Additionally, in the US, 23-43% of healthcare providers were not providing HPV tests to women 
ages 30-65 years old.43,44 Providers must also manage the multiplicity of clinical guidelines for 
cervical cancer screening from various professional organizations45 and stay abreast of changes 
in these guidelines.46 Thus, additional research is needed in the area of provider 
recommendation for cervical cancer screening and shared decision-making between patients 
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 Overall, demographic characteristics were not associated with willingness for an HPV 
test, with the exception of educational attainment. Women with a college education were least 
likely to be willing to receive the HPV test instead of the Pap test compared to women with a 
high school degree; yet, this difference was not observed when the time interval was added to 
the outcome variable. This may be the result of knowledge or attitudes regarding preventive 
health practices varying by educational attainment. For example, those with a college education 
may desire to continue with a Pap test, but not necessarily if this means less frequent screening 
intervals. A previous study among a national sample of women found that women’s knowledge 
about HPV also varied by educational attainment,47 which may need to be considered when 
developing strategies to promote HPV testing.  
 The study findings should be considered in the context of the limitations. First, the 
sampling frame for this study is derived from an online panel of English speakers and may not 
be completely generalizable to U.S. women. The exclusion criteria for this study were women 
who had a hysterectomy; however, we did not exclude women who were diagnosed with 
cervical abnormalities due to the concern of self-report status of this criterion. Additionally, at the 
time of survey distribution, the cervical cancer screening guidelines were in a draft form on the 
taskforce website.28 The draft guidelines had the option of primary HPV testing or Pap testing 
only (a change from Pap testing only or co-testing); however, the finalized guidelines released in 
September 2018 also included the option of co-testing. Therefore, the data gathered for this 
study did not include the co-testing option. Finally, these data are self-reported, so items such 
as past cervical cancer screening behavior may be misclassified due to retrospective bias.  
 
Conclusion 
 Recognizing barriers and facilitators to willingness to transition to primary HPV testing 
over Pap testing is needed as the United States has updated guidelines for cervical cancer 
screening. Emphasizing positive attributes of HPV testing compared to Pap testing and provider 
recommendations may promote the use of this screening technique as this guideline transition 
takes place. It is particularly promising that over half of the women in this study are willing to get 
the HPV test instead of the Pap test and more than half of the respondents were willing to get 
the HPV test every 5 years instead of the Pap test every 3 years, given that studies from only a 
decade ago found strongly negative emotional expressions among women who received an 
HPV positive test result. These study findings do not preclude continued educational efforts 
aimed at reassuring women that the majority of HPV infections are transitory, as any test result 
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indicates a possible positive trend in women choosing a prevention strategy that might 
previously have been untenable. Future research should utilize dissemination and 
implementation science approaches to promote cervical cancer screening guidelines transitions 
in practice. With improved sensitivity of HPV testing, adoption of this guideline change has the 
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Table 1.  Frequencies and adjusted odds of willingness for HPV testing among US women 
(n=812) 
 Willingness for HPV Test instead of Pap 
Test 
Willingness for HPV Test Every 5 Years 







365 (45.0) aOR (95% CI) 
Willing, 
n (%) 




347 (43.0) aOR (95% CI) 
Information 
HPV Knowledge Scale 
a,b
 9.0 (4.2) 7.0 (4.8) 1.08 (1.04, 1.13) 9.0 (4.2) 6.9 (4.9) 1.08 (1.04, 1.13) 
Motivation 
HPV Testing Attitude Scale 
a,c
 
23.0 (4.7) 18.2 (5.3) 1.14 (1.10, 1.19) 22.9 (4.6) 18.1 (5.5) 1.15 (1.11, 1.20) 
Social Norms (People important to me think I should have the HPV test instead of the Pap test) 
Agree 320 (71.6) 125 (34.3) 2.01 (1.37, 2.95) 320 (68.8) 125 (36.0) 1.76 (1.20, 2.57) 
Neither Agree/Disagree 115 (25.7) 188 (51.5) 1 (Referent) 126 (27.1) 177 (51.0) 1 (Referent) 
Disagree 12 (2.7) 52 (14.3) 0.34 (0.16, 0.74) 19 (4.1) 45 (13.0) 0.62 (0.31, 1.24) 
HPV Test Benefit: Less time at doctor’s office 
     Yes 380 (85.0) 217 (59.5) 1.81 (1.13, 2.91) 386 (83.0) 211 (60.8) 1.36 (0.86, 2.16) 
     No 67 (15.0) 148 (40.6) 1 (Referent) 79 (17.0) 136 (39.2) 1 (Referent) 
HPV Test Benefit: Less frequent discomfort 
     Yes 368 (82.3) 203 (55.6) 1.61 (1.01, 2.58) 376 (80.9) 195 (56.2) 1.61 (1.02, 2.54) 
     No 79 (17.7) 162 (44.4) 1 (Referent) 89 (19.1) 152 (43.8) 1 (Referent) 
Worried about Cervical Cancer 
Very/Quite  103 (23.0) 58 (15.9) 2.58 (1.48, 4.51) 101 (21.7) 60 (17.3) 2.01 (1.17, 3.43) 
Somewhat/Slightly  248 (55.5) 193 (52.9) 1.55 (1.01, 2.38) 263 (56.6) 178 (51.3) 1.59 (1.05, 2.41) 
Not  96 (21.5) 114 (31.2) 1 (Referent) 101 (21.7) 109 (31.4) 1 (Referent) 
What Worries You More 
Abnormal HPV Test 65 (14.5) 25 (6.9) 2.21 (1.21, 4.02) 60 (12.9) 30 (8.7) 1.22 (0.70, 2.13) 
Abnormal Pap test 68 (15.2) 46 (12.6) 1.09 (0.66, 1.80) 74 (15.9) 40 (11.5) 1.21 (0.73, 2.00) 
Equally Worrying 279 (62.4) 210 (57.5) 1 (Referent) 292 (62.8) 197 (56.8) 1 (Referent) 
Neither 35 (7.8) 84 (23.0) 0.84 (0.48, 1.50) 39 (8.4) 80 (23.1) 0.87 (0.50, 1.51) 
Behavioral Skills 
Easier to Decide: Provider Recommendation 
     Yes 394 (88.1) 218 (59.7) 2.43 (1.53, 3.87) 400 (86.0) 212 (61.1) 1.71 (1.10, 2.67) 
     No 53 (11.9) 147 (40.3) 1 (Referent) 65 (14.0) 135 (38.9) 1 (Referent) 
Harder to Decide: Stigma at having HPV 
     Yes 180 (40.3) 116 (31.8) 0.69 (0.47, 1.02) 184 (39.6) 112 (32.3) 0.77 (0.53, 1.12) 
     No 267 (59.7) 249 (68.2) 1 (Referent) 281 (60.4) 235 (67.7) 1 (Referent) 
Follows Cervical Cancer Screening Guidelines 
     Yes 345 (77.2) 235 (64.4) 1.52 (1.02, 2.26) 362 (77.9) 218 (62.8) 1.73 (1.18, 2.54) 
     No 102 (22.8) 130 (35.6) 1 (Referent) 103 (22.2) 129 (37.2) 1 (Referent) 
Demographics 
Educational Attainment 
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High school 129 (28.9) 95 (26.0) 1 (Referent) 130 (28.0) 94 (27.1) 1 (Referent) 
Some college/technical 
school 
164 (36.7) 132 (36.2) 0.79 (0.50, 1.25) 162 (34.8) 134 (38.6) 0.71 (0.46, 1.11) 
College 134 (30.0) 112 (30.7) 0.58 (0.35, 0.94) 151 (32.5) 95 (27.4) 0.88 (0.55, 1.41) 
Marital Status 
     Single 116 (26.0) 114 (31.2) 0.73 (0.48, 1.13) 124 (26.7) 106 (30.6) 0.89 (0.59, 1.36) 
     Married 235 (52.6) 169 (46.3) 1 (Referent) 238 (51.2) 166 (47.8) 1 (Referent) 
     Other 96 (21.5) 82 (22.5) 1.05 (0.66, 1.67) 103 (22.2) 75 (21.6) 1.27 (0.81, 2.00) 
Age 
     30-39 years 179 (40.0) 144 (39.5) 1 (Referent) 181 (38.9) 142 (40.9) 1 (Referent) 
     40-49 years 111 (24.8) 80 (21.9) 1.23 (0.77, 1.96) 120 (25.8) 71 (20.5) 1.56 (0.99, 2.47) 
     50-59 years 103 (23.0) 88 (24.1) 1.02 (0.63, 1.65) 108 (23.2) 83 (23.9) 1.15 (0.73, 1.82) 
     60-65 years 54 (12.1) 53 (14.5) 0.96 (0.53, 1.72) 56 (12.0) 51 (14.7) 1.08 (0.61, 1.91) 
Hispanic or Latina 
     Yes 87 (19.5) 64 (17.5) 0.73 (0.45, 1.18) 95 (20.4) 56 (16.1) 0.95 (0.59, 1.53) 
     No 360 (80.5) 301 (82.5) 1 (Referent) 370 (79.6) 291 (83.9) 1 (Referent) 
Race 
Black/African American 102 (22.8) 85 (23.3) 0.80 (0.51, 1.25) 106 (22.8) 81 (23.3) 0.84 (0.54, 1.30) 
Other  39 (8.7) 33 (9.0) 0.64 (0.34, 1.22) 40 (8.6) 32 (9.2) 0.66 (0.35, 1.24) 
White or Caucasian 306 (68.5) 247 (67.7) 1 (Referent) 319 (68.6) 234 (67.4) 1 (Referent) 
a
 Scale values in these rows are displayed as mean (standard deviation) instead of n (%). 
b
 Knowledge scale range 0-16. 
c
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Highlights 
- Most women were willing to receive an HPV test for cervical cancer screening. 
- Information and motivation factors increased women’s willingness for an HPV test. 
- Provider recommendation may be a critical facilitator for HPV testing uptake. 
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